Gilles Romieu

Gilles Romieu

UNVERIFIED PROFILE

Are you Gilles Romieu?   Register this Author

Register author
Gilles Romieu

Gilles Romieu

Publications by authors named "Gilles Romieu"

Are you Gilles Romieu?   Register this Author

70Publications

2380Reads

26Profile Views

Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the "APAD1" randomized controlled trial.

BMC Cancer 2019 Jul 25;19(1):737. Epub 2019 Jul 25.

Val d'Aurelle Montpellier Cancer Institute (ICM), 208, Avenue des Apothicaires, Parc Euromédecine, 34298 Montpellier Cedex 5, France; Montpellier University, 34000, Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5896-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659309PMC
July 2019

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nature 2019 02;566(7742):E1

Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41586-019-0883-2
Publisher Site
http://dx.doi.org/10.1038/s41586-019-0883-2DOI Listing
February 2019

Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers.

Breast Cancer Res Treat 2017 Oct 6;165(3):611-621. Epub 2017 Jul 6.

Institut Régional du Cancer de Montpellier - Val d'Aurelle, 208 avenue des Apothicaires, 34298, Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-017-4373-7DOI Listing
October 2017

Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?

Int J Cancer 2016 11 6;139(10):2299-311. Epub 2016 Aug 6.

Department of Medical Oncology, Institut Régional Du Cancer Montpellier ICM, Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.30290DOI Listing
November 2016

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nature 2016 06 2;534(7605):47-54. Epub 2016 May 2.

Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature17676DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910866PMC
June 2016

Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.

Breast Cancer Res Treat 2016 06 11;157(2):307-318. Epub 2016 May 11.

Medical Oncology Department, Institut Claudius Regaud, IUCT-Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-3828-6DOI Listing
June 2016

High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.

BMC Cancer 2015 Dec 18;15:986. Epub 2015 Dec 18.

Department of Oncogenetics, Montpellier Cancer Institute Val d'Aurelle, 208, rue des Apothicaires, Montpellier, F-34298, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1977-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4683760PMC
December 2015

Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.

J Clin Oncol 2015 Apr 23;33(10):1136-42. Epub 2015 Feb 23.

Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA; Thomas M. Suter, Bern University Hospital, Bern, Switzerland; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York; Marc L. Citron, Hofstra North Shore-Long Island Jewish School of Medicine, New Hyde Park, NY; Luc Dirix, Sint-Augustinus Hospital, Antwerp, Belgium; Gilles Romieu, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier; Mario Campone, Institut de Cancérologie de l'Ouest/René Gauducheau, Nantes Saint-Herblain, France; Claudio Zamagni, Policlinico Sant'Orsola-Malpighi Hospital, Bologna; Luca Gianni, San Raffaele Hospital, Milan, Italy; and Na Xu and Melanie Smitt, Genentech, South San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.7782DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657012PMC
April 2015

Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?

Crit Rev Oncol Hematol 2014 Dec 30;92(3):235-57. Epub 2014 Jul 30.

University Institute of Pathology, CHUV, rue du Bugnon 25, 1011 Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2014.07.003DOI Listing
December 2014

[Breast cancer: radiotherapy and estrogen signaling].

Bull Cancer 2014 Jul-Aug;101(7-8):714-7

INSERM U896, Institut régional du cancer de Montpellier, Département de radiothérapie oncologique, 208 rue des Apothicaires, Parc Euromédecine, 34298 Montpellier Cedex 05, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2014.1954DOI Listing
September 2014

Cancer-related fatigue in breast cancer patients after surgery: a multicomponent model using partial least squares-path modeling.

Psychooncology 2014 Apr 22;23(4):444-51. Epub 2013 Oct 22.

Laboratory Epsylon EA 4556, University of Montpellier 1 and 3, Montpellier, France; University Department of Adult Psychiatry, La Colombière Hospital, Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pon.3438DOI Listing
April 2014

[Vitamin D and breast cancer: physiopathology, biological and clinical implications].

Bull Cancer 2014 Mar;101(3):266-82

ICM Val-d'Aurelle, service d'oncologie médicale, 208, rue des Apothicaires, 34298 Montpellier cedex 05, France, ICM Val-d'Aurelle, unité de recherche translationnelle, 208, rue des Apothicaires, 34298 Montpellier cedex 05, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2013.1826DOI Listing
March 2014

Adapted physical activity and diet (APAD) during adjuvant breast cancer therapy: design and implementation of a prospective randomized controlled trial.

Contemp Clin Trials 2013 Nov 4;36(2):531-43. Epub 2013 Oct 4.

Laboratory Epsylon, EA 4556 Dynamics of Human Abilities & Health Behaviors, University of Montpellier, 4 boulevard Henri IV, F-34000 Montpellier, France; INSERM UMR 1027, Paul Sabatier University, 37 allées Jules Guesde, F-31000 Toulouse, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cct.2013.09.016DOI Listing
November 2013

Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.

Breast 2013 Oct 3;22(5):993-8. Epub 2013 Jul 3.

Department of Radiation Oncology, Val d'Aurelle Cancer Institute, 208 rue des Apothicaires, 34298 Montpellier, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2013.05.011DOI Listing
October 2013

Risk-adapted, dose escalation study of weekly docetaxel in the first-line treatment of elderly patients with advanced cancer.

J Geriatr Oncol 2013 Apr 14;4(2):122-7. Epub 2012 Dec 14.

Department of Medical Oncology, CRLC Val d'Aurelle, Montpellier, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2012.11.002DOI Listing
April 2013

Comparative performances of prognostic indexes for breast cancer patients presenting with brain metastases.

BMC Cancer 2013 Feb 8;13:70. Epub 2013 Feb 8.

Department of Radiation Oncology, Val d'Aurelle Cancer Institute, 208 rue des apothicaires, Montpellier 34298, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-13-70DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599004PMC
February 2013

Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy.

Breast Cancer Res Treat 2012 Jul 6;134(2):709-17. Epub 2012 May 6.

Département d'Oncologie Médicale, CRLC Val d'Aurelle-Paul Lamarque, 208, rue des Apothicaires, 34298 Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-012-2084-7DOI Listing
July 2012

Etoposide, mitomycin, and methotrexate combination in heavily treated breast cancer: a retrospective study.

Breast Cancer 2012 Jan 19;19(1):16-22. Epub 2010 Nov 19.

Department of Medical Oncology, CRLC Val d'Aurelle, 208 rue des Apothicaires, 34298, Montpellier Cedex 5, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-010-0240-7DOI Listing
January 2012

[Hormone receptors and HER-2 changes during breast cancer progression: clinical implications].

Bull Cancer 2011 Oct;98(9):1059-70

CRLC Val-d'Aurelle, service d'oncologie médicale, Montpellier Cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2011.1434DOI Listing
October 2011

Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial.

Breast Cancer Res Treat 2009 Sep 23;117(1):69-75. Epub 2008 Nov 23.

Institut Bergonié, Centre Régional de Lutte Contre le Cancer de Bordeaux et du Sud-Ouest, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-008-0141-zDOI Listing
September 2009

Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial.

Anticancer Res 2007 Jul-Aug;27(4C):2689-96

Departments of Medical Oncology, Centre René Huguenin, 35 rue daily, 92210 St-Cloud, France.

View Article

Download full-text PDF

Source
August 2007

Letrozole sensitizes breast cancer cells to ionizing radiation.

Breast Cancer Res 2005 7;7(1):R156-63. Epub 2004 Dec 7.

Department of Radiation Oncology, CRLC Val d'Aurelle, Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr969DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064115PMC
January 2006

Reducing the time interval between cycles using standard doses of docetaxel and lenogastrim support: a feasibility study.

Cancer 2004 Jul;101(1):178-82

Department of Medical Oncology, CRLC Val d'Aurelle, Parc Euromédecine, 34298 Montpellier Cedex 5, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.20351DOI Listing
July 2004

Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.

Cancer 2004 Mar;100(6):1257-61

Department of Medical Oncology, Centre Régional de Lutte contre le Cancer Val d'Aurelle, Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.20100DOI Listing
March 2004

Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site.

Anticancer Res 2003 May-Jun;23(3C):2801-4

Centre Régional de Lutte contre le Cancer Val d'Aurelle Montpellier, Parc Euromédecine, 34298-Montpellier, France.

View Article

Download full-text PDF

Source
September 2003